Bortezomib retreatment is effective in relapsed multiple
myeloma patients - real-life clinical practice data

J 2020

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Lucie BROŽOVÁ, I. SPICKA, V. MAISNAR et. al.

Základní údaje

Originální název

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

Autoři

ŠTORK, Martin (203 Česká republika), Sabina ŠEVČÍKOVÁ (203 Česká republika, domácí), Lucie BROŽOVÁ (203 Česká republika, domácí), I. SPICKA (203 Česká republika), V. MAISNAR (203 Česká republika), J. MINARIK (203 Česká republika), A. JUNGOVA (203 Česká republika), E. GREGORA (203 Česká republika), Roberta VELICHOVÁ (703 Slovensko, domácí), R. HAJEK (203 Česká republika), T. JELINEK (203 Česká republika) a Luděk POUR (203 Česká republika, garant)

Vydání

Neoplasma, Bratislava, Slovenská akademie vied, 2020, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.575

Kód RIV

RIV/00216224:14110/20:00115970

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2019_190430N383

UT WoS

000542659200021

Klíčová slova anglicky

multiple myeloma; bortezomib; proteasome inhibitor; repeated treatment; relapse

Štítky

14110518, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 14. 7. 2020 12:17, Mgr. Tereza Miškechová

Anotace

V originále

Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. 'I he aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.

Citovat

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Lucie BROŽOVÁ, I. SPICKA, V. MAISNAR, J. MINARIK, A. JUNGOVA, E. GREGORA, Roberta VELICHOVÁ, R. HAJEK, T. JELINEK a Luděk POUR. Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data. Neoplasma. Bratislava: Slovenská akademie vied, 2020, roč. 67, č. 1, s. 178-184. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2019_190430N383.

@article{1670231,
   author = {Štork, Martin and Ševčíková, Sabina and Brožová, Lucie and Spicka, I. and Maisnar, V. and Minarik, J. and Jungova, A. and Gregora, E. and Velichová, Roberta and Hajek, R. and Jelinek, T. and Pour, Luděk},
   article_location = {Bratislava},
   article_number = {1},
   doi = {http://dx.doi.org/10.4149/neo_2019_190430N383},
   keywords = {multiple myeloma; bortezomib; proteasome inhibitor; repeated treatment; relapse},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data},
   url = {http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6465&category_id=160&option=com_virtuemart&vmcchk=1&Itemid=1},
   volume = {67},
   year = {2020}
}

TY  - JOUR
ID  - 1670231
AU  - Štork, Martin - Ševčíková, Sabina - Brožová, Lucie - Spicka, I. - Maisnar, V. - Minarik, J. - Jungova, A. - Gregora, E. - Velichová, Roberta - Hajek, R. - Jelinek, T. - Pour, Luděk
PY  - 2020
TI  - Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data
JF  - Neoplasma
VL  - 67
IS  - 1
SP  - 178-184
EP  - 178-184
PB  - Slovenská akademie vied
SN  - 00282685
KW  - multiple myeloma
KW  - bortezomib
KW  - proteasome inhibitor
KW  - repeated treatment
KW  - relapse
UR  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6465&category_id=160&option=com_virtuemart&vmcchk=1&Itemid=1
L2  - http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=6465&category_id=160&option=com_virtuemart&vmcchk=1&Itemid=1
N2  - Nowadays, bortezomib, a proteasome inhibitor, is widely used in treatment of newly diagnosed or relapsed multiple myeloma. 'I he aim of this study was to analyze efficiency of bortezomib retreatment in patients with relapsed or refractory multiple myeloma. From 2004 to 2016, 283 patients were retrospectively evaluated at all hematological centers in the Czech Republic. Bortezomib was administered at the standard dosing and in combined therapy with corticosteroids, chemotherapy or thalidomide. Before bortezomib retreatment, 61% of patients received previous lenalidomide treatment, 40.6% autologous transplantation, and median number of prior lines of therapy was three. In total, 21% of patients were refractory to the first bortezomib treatment. In bortezomib retreatment, overall response rate was 34.5%, median progression-free survival was 7.8 months (95% CI: 6.7-8.9), median duration of response was 10.5 months (95% CI: 8.0-13.0) and median overall survival was 20.3 months (95% CI: 17.9-22.7). Grade 3-4 adverse events included thrombocytopenia, neutropenia, anemia and infection. Neuropathy grade 2 or higher occurred in 19.4% of patients. We conclude that bortezomib retreatment is an effective and safe therapeutic alternative for relapsed or refractory multiple myeloma patients.
ER  -

ŠTORK, Martin, Sabina ŠEVČÍKOVÁ, Lucie BROŽOVÁ, I. SPICKA, V. MAISNAR, J. MINARIK, A. JUNGOVA, E. GREGORA, Roberta VELICHOVÁ, R. HAJEK, T. JELINEK a Luděk POUR. Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data. \textit{Neoplasma}. Bratislava: Slovenská akademie vied, 2020, roč.~67, č.~1, s.~178-184. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2019\_{}190430N383.

Podrobný výpis o publikaci